$HALO
HALOZYME THERAPEUTICS, INC.

2020 Q2 Form 10-Q Financial Statement

#000115903620000037 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $55.22M $39.15M $56.95M
YoY Change 41.06% 11.21% 84.47%
Cost Of Revenue $5.740M $1.877M $4.649M
YoY Change 205.81% 124.52% 52.33%
Gross Profit $597.0K $3.883M $3.741M
YoY Change -84.63% 6.47% -0.21%
Gross Profit Margin 1.08% 9.92% 6.57%
Selling, General & Admin $10.98M $17.34M $18.01M
YoY Change -36.7% 20.8% 32.83%
% of Gross Profit 1838.36% 446.51% 481.32%
Research & Development $8.951M $33.91M $31.33M
YoY Change -73.6% -15.41% -17.51%
% of Gross Profit 1499.33% 873.29% 837.42%
Depreciation & Amortization $800.0K $1.000M $1.000M
YoY Change -20.0% 66.67% 76.68%
% of Gross Profit 134.0% 25.75% 26.73%
Operating Expenses $25.67M $53.13M $53.98M
YoY Change -51.69% -3.89% -1.1%
Operating Profit $29.56M -$13.98M $2.966M
YoY Change -311.45% -30.37% -112.51%
Interest Expense $5.004M $2.613M $3.205M
YoY Change 91.5% -45.22% -38.72%
% of Operating Profit 16.93% 108.06%
Other Income/Expense, Net $1.324M $1.983M $2.057M
YoY Change -33.23% 0.0% 23.32%
Pretax Income $25.88M -$14.61M $1.818M
YoY Change -277.14% -36.1% -106.67%
Income Tax $58.00K $17.00K $22.00K
% Of Pretax Income 0.22% 1.21%
Net Earnings $25.82M -$14.62M $1.796M
YoY Change -276.54% -36.12% -106.54%
Net Earnings / Revenue 46.75% -37.36% 3.15%
Basic Earnings Per Share $0.19 -$0.10 $0.01
Diluted Earnings Per Share $0.19 -$0.10 $0.01
COMMON SHARES
Basic Shares Outstanding 135.9M shares 145.4M shares 144.7M shares
Diluted Shares Outstanding 138.1M shares 145.4M shares 147.5M shares

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $385.4M $287.5M $328.7M
YoY Change 34.07% -27.93% -24.21%
Cash & Equivalents $133.6M $67.04M $60.60M
Short-Term Investments $251.8M $220.4M $268.1M
Other Short-Term Assets $29.20M $28.10M $20.90M
YoY Change 3.91% 32.55% 5.56%
Inventory $48.27M $43.90M $31.24M
Prepaid Expenses $32.43M $19.92M $9.346M
Receivables $37.40M $32.22M $28.16M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $500.4M $391.7M $409.0M
YoY Change 27.74% -15.22% -15.57%
LONG-TERM ASSETS
Property, Plant & Equipment $11.17M $15.08M $14.54M
YoY Change -25.93% 214.87% 194.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.50M $11.00M $5.500M
YoY Change 40.91% 39.24% -9.84%
Total Long-Term Assets $26.64M $26.12M $20.07M
YoY Change 1.97% 105.35% 82.5%
TOTAL ASSETS
Total Short-Term Assets $500.4M $391.7M $409.0M
Total Long-Term Assets $26.64M $26.12M $20.07M
Total Assets $527.0M $417.8M $429.1M
YoY Change 26.13% -11.99% -13.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.067M $12.47M $4.089M
YoY Change -67.38% 101.5% 12.71%
Accrued Expenses $21.26M $45.56M $43.66M
YoY Change -53.34% 30.06% 36.92%
Deferred Revenue $748.0K $6.511M $4.247M
YoY Change -88.51%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $70.88M $86.66M
YoY Change -100.0% -18.5% 5.1%
Total Short-Term Liabilities $26.07M $135.4M $138.7M
YoY Change -80.75% 2.26% 16.3%
LONG-TERM LIABILITIES
Long-Term Debt $390.1M $14.10M $18.70M
YoY Change 2666.67% -82.17% -81.79%
Other Long-Term Liabilities $4.627M $6.532M $7.149M
YoY Change -29.16% 182.28% 188.38%
Total Long-Term Liabilities $4.627M $6.532M $7.149M
YoY Change -29.16% 182.28% 188.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.07M $135.4M $138.7M
Total Long-Term Liabilities $4.627M $6.532M $7.149M
Total Liabilities $30.70M $141.9M $145.8M
YoY Change -78.37% 5.35% 19.81%
SHAREHOLDERS EQUITY
Retained Earnings -$584.0M -$544.3M -$529.6M
YoY Change 7.29% 8.54% 10.67%
Common Stock $688.5M $803.9M $789.6M
YoY Change -14.36% 6.18% 6.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $105.6M $260.1M $260.0M
YoY Change
Total Liabilities & Shareholders Equity $527.0M $417.8M $429.1M
YoY Change 26.13% -11.99% -13.39%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income $25.82M -$14.62M $1.796M
YoY Change -276.54% -36.12% -106.54%
Depreciation, Depletion And Amortization $800.0K $1.000M $1.000M
YoY Change -20.0% 66.67% 76.68%
Cash From Operating Activities $3.200M -$24.80M -$4.424M
YoY Change -112.9% 31.91% -80.05%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$1.400M $927.0K
YoY Change -64.29% 180.0% 10.49%
Acquisitions
YoY Change
Other Investing Activities $12.40M $48.90M $29.70M
YoY Change -74.64% -779.17% -184.62%
Cash From Investing Activities $11.90M $47.50M $28.81M
YoY Change -74.95% -725.0% -180.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.60M -16.30M -$21.73M
YoY Change -183.44% 0.0% 71.77%
NET CHANGE
Cash From Operating Activities 3.200M -24.80M -$4.424M
Cash From Investing Activities 11.90M 47.50M $28.81M
Cash From Financing Activities 13.60M -16.30M -$21.73M
Net Change In Cash 28.70M 6.400M $2.659M
YoY Change 348.44% -114.99% -103.76%
FREE CASH FLOW
Cash From Operating Activities $3.200M -$24.80M -$4.424M
Capital Expenditures -$500.0K -$1.400M $927.0K
Free Cash Flow $3.700M -$23.40M -$5.351M
YoY Change -115.81% 27.87% -76.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0001159036
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144725164 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
136671854 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144725164 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
136671854 shares
CY2020Q2 us-gaap Noncurrent Assets
NoncurrentAssets
0 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7200000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7200000 USD
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0231
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0167
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0183
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0183
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Entity Registrant Name
EntityRegistrantName
HALOZYME THERAPEUTICS, INC.
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32335
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0488686
dei Entity Address Address Line1
EntityAddressAddressLine1
11388 Sorrento Valley Road
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
794-8889
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
HALO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
137026670 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133606000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120179000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
251840000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
301083000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37401000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59442000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
48271000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
29359000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29240000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33373000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
500358000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
543436000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11169000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10855000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
14970000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
11083000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2020Q2 us-gaap Assets
Assets
526997000 USD
CY2019Q4 us-gaap Assets
Assets
565874000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4067000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6434000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21258000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55649000 USD
CY2020Q2 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
748000 USD
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4012000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
19542000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26073000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85637000 USD
CY2020Q2 us-gaap Deferred Credits And Other Liabilities Noncurrent
DeferredCreditsAndOtherLiabilitiesNoncurrent
641000 USD
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1247000 USD
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
390079000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
383045000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4627000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4180000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
137000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
137000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
688318000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
695066000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1086000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
240000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-583964000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-603678000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
105577000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
91765000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
526997000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
565874000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55221000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39148000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80575000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96097000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5740000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1877000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11527000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6526000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8951000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33910000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19109000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65238000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10975000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17338000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23607000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35344000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
25666000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
53125000 USD
us-gaap Costs And Expenses
CostsAndExpenses
54243000 USD
us-gaap Costs And Expenses
CostsAndExpenses
107108000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
29555000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13977000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
26332000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-11011000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1324000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1983000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3803000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4040000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
5004000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
2613000 USD
us-gaap Interest Expense
InterestExpense
10352000 USD
us-gaap Interest Expense
InterestExpense
5818000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
25875000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14607000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19783000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12789000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
69000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
25817000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14624000 USD
us-gaap Net Income Loss
NetIncomeLoss
19714000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12828000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> drug delivery</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">technology with the collaborators’ proprietary compounds.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant, (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> drug delivery technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (“Alexion”) and ARGENX BVBA (“argenx”). We receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from royalties and fees from ENHANZE collaborations and the sales and/or royalties of our approved products will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.</span></div>
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135935000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
145411000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136572000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
145051000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138084000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145411000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138837000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145051000 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
25817000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14624000 USD
us-gaap Net Income Loss
NetIncomeLoss
19714000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12828000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1072000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
332000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
843000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
667000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-6000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
2000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-5000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
1000 USD
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3000 USD
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26892000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14295000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20560000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12161000 USD
us-gaap Net Income Loss
NetIncomeLoss
19714000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12828000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8788000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19308000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1681000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2024000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6988000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
554000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-197000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1733000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
597000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3870000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
998000 USD
halo Deferred Rent Expense
DeferredRentExpense
-489000 USD
halo Deferred Rent Expense
DeferredRentExpense
-203000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-10000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
8000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22041000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2214000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18912000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21275000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-443000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13540000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37524000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1687000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1550000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29210000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
78237000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
233684000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
128136000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
312249000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
629000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2295000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
738000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50008000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76270000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
19560000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
41973000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
53570000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
38099000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4018000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-35031000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-37955000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13427000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9105000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120679000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58436000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
134106000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67541000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
156000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
545000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12828000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
260052000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1609000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
165000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
58042000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4257000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18382000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
88000 shares
CY2020Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1996000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
1075000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
25817000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
105577000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
91765000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8788000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38099000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
3792000 shares
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
53570000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-65000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-65000 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
846000 USD
us-gaap Net Income Loss
NetIncomeLoss
19714000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
105577000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
260047000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9833000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4467000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
329000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14624000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
260052000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
248887000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19308000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4018000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
667000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div>The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“ U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
halo Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
P90D
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15700000 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
25817000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14624000 USD
us-gaap Net Income Loss
NetIncomeLoss
19714000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12828000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135935000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145411000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136572000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145051000 shares
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2149000 shares
CY2019Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2265000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138084000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145411000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138837000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145051000 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
250741000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1099000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
251840000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
300829000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
273000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
301083000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
251840000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
274805000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
26278000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
251840000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
301083000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55221000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39148000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80575000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
96097000 USD
halo Proceeds From Partner Of License And Collaborative Agreement
ProceedsFromPartnerOfLicenseAndCollaborativeAgreement
57700000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37401000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59442000 USD
CY2020Q2 us-gaap Deferred Revenue
DeferredRevenue
1389000 USD
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
5259000 USD
CY2020Q2 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
1400000 USD
CY2020Q2 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
1400000 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
700000 USD
CY2020Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
877703000 USD
CY2020Q2 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
3705000 USD
CY2019Q4 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
35649000 USD
CY2020Q2 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
15476000 USD
CY2019Q4 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
3850000 USD
CY2020Q2 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
15983000 USD
CY2019Q4 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
17149000 USD
CY2020Q2 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
3082000 USD
CY2019Q4 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
3591000 USD
CY2020Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
38246000 USD
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
60239000 USD
CY2020Q2 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
845000 USD
CY2019Q4 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
797000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37401000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59442000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7332000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2769000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14835000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15710000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
26104000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10880000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
48271000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
29359000 USD
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
32428000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30156000 USD
CY2020Q2 halo Prepaidresearchanddevelopment
Prepaidresearchanddevelopment
623000 USD
CY2019Q4 halo Prepaidresearchanddevelopment
Prepaidresearchanddevelopment
4964000 USD
CY2020Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3310000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3655000 USD
CY2020Q2 us-gaap Other Assets
OtherAssets
7849000 USD
CY2019Q4 us-gaap Other Assets
OtherAssets
5681000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
44210000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
44456000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
14970000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
11083000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29240000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33373000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross Excluding Capital Leased Assets
PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets
17902000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross Excluding Capital Leased Assets
PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets
17748000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
11285000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
10742000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net Excluding Capital Leased Assets
PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets
6617000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net Excluding Capital Leased Assets
PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets
7006000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4552000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3849000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11169000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10855000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000 USD
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000.0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1700000 USD
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000000.0 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
900000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
800000 USD
CY2020Q2 halo Accrued Outsourced Research And Development Expenses Current
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent
582000 USD
CY2019Q4 halo Accrued Outsourced Research And Development Expenses Current
AccruedOutsourcedResearchAndDevelopmentExpensesCurrent
8423000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5005000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27888000 USD
CY2020Q2 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
8011000 USD
CY2019Q4 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
9173000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5539000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7876000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6684000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6469000 USD
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
25821000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
59829000 USD
CY2020Q2 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
4563000 USD
CY2019Q4 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
4180000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21258000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55649000 USD
CY2020Q2 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
200000 USD
CY2019Q2 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
200000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
600000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
700000 USD
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
300000 USD
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
400000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1200000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1300000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
900000 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
800000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1700000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 USD
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1389000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5259000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
748000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4012000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
641000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1247000 USD
CY2019Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
447400000 USD
CY2019Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200000000.0 USD
CY2019Q4 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
6900000 USD
CY2019Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
26100000 USD
CY2019Q4 halo Non Convertible Borrowing Ratefor Similar Debt Percent
NonConvertibleBorrowingRateforSimilarDebtPercent
0.0519
CY2019Q4 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
65600000 USD
CY2019Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
447400000 USD
CY2020Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
585800000 USD
CY2019Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
461100000 USD
CY2020Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
2930000 USD
CY2019Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
26100000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4257000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9833000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8788000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19308000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4257000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9833000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8788000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19308000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
100000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1400000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2900000 shares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000.0 USD
CY2019Q4 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
400000 shares
CY2019Q4 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
6900000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
3188795 shares
CY2020Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
16.15
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
51574000 USD
CY2020Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
88307 shares
CY2020Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
22.58
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1996000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
3277102 shares
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
53570000 USD
CY2020Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
500000 shares
CY2020Q1 halo Treasury Stock Acquired Fee Cost Per Share
TreasuryStockAcquiredFeeCostPerShare
0.02
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1679000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2872000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2694000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
119000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7364000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
680000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6684000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D

Files In Submission

Name View Source Status
R41.htm Edgar Link pending
0001159036-20-000037-index-headers.html Edgar Link pending
0001159036-20-000037-index.html Edgar Link pending
0001159036-20-000037.txt Edgar Link pending
0001159036-20-000037-xbrl.zip Edgar Link pending
ex101halozymepsuawarda.htm Edgar Link pending
ex31110qq22020.htm Edgar Link pending
ex31210qq22020.htm Edgar Link pending
ex3210qq22020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
halo-20200630.xsd Edgar Link pending
halo-20200630_cal.xml Edgar Link unprocessable
halo-20200630_def.xml Edgar Link unprocessable
halo-20200630_lab.xml Edgar Link unprocessable
halo-20200630_pre.xml Edgar Link unprocessable
haloq220-10q.htm Edgar Link pending
haloq220-10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slide1b33.jpg Edgar Link pending
slide2b15.jpg Edgar Link pending